お知らせ

Takei M, Kitamura N, Nagasawa Y, Tsuzuki H, Iwata M, Nagatsuka Y, Imai K, Fujiwara S,

Nakamura H

Are viral infections key inducers of autoimmune diseases?-Focus on Epstein-Barr virus-
Viruses, accepted (IF: 5.818)

• 中村英樹　Sjögren症候群　リウマチ病学テキスト、p209-17, 2022年5月、南江堂

• 八田善弘　専門医のための血液学（共著）、2022年3月、医学書院

• Takahashi H, Miura K, Nakagawa M. et al.　 Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study.　 Hematol Oncol. Online ahead of print.
• Tsuboi H, Nakamura H, Takei M et al. Abatacept Ameliorates Both Glandular and Extraglandular Involvements in Patients With Sjögren’s Syndrome Associated with Rheumatoid Arthritis: Findings from an Open-Label, Multicenter, 1-Year, Prospective Study: the ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren’s Syndrome Endocrinopathy) and ROSE II trials. Mod Rheumatol. Online ahead of print.
• Nakamura H, Nagasawa Y, Kobayashi H. et al.　 Successful Treatment of SARS-CoV-2 Vaccination-related Activation of Rheumatoid Arthritis with Positive Findings for Epstein-Barr Virus.　Intern Med. 2022 Jul 1;61(13):2073-2076.
• Miura K, Takahashi H, Nakagawa M. et al.　 Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.　 Expert Rev Anticancer Ther. 2022 Jun;22(6):583-595.
• Asatani S, Kobayashi H, Nagasawa Y. et al.　 Successful treatment for eosinophilic granulomatosis with polyangiitis causing severe myocarditis followed by cardiac magnetic resonance.　Mod Rheumatol Case Rep. 2022 Jun 24;6(2):248-253.
• Iriyama N, Miura K, Uchino Y. et al.　 Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia.　Chemotherapy. 2022;67(2):96-101.
• Nakamura H, Tsukamoto M, Nagasawa Y. et al.　 Does HTLV-1 Infection Show Phenotypes Found in Sjögren’s Syndrome?　Viruses. 2022 Jan 6;14(1):100.
• Tsutsumi D, Hayama T, Miura K, et al. A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma. Int J Clin Pharm. 2022 Apr;44(2):366-373.
• Yasuda T, Sanada M, Kawazu M, et al. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutation. Blood. 2022 Mar 24;139(12):1850-1862.
• Sugiura I, Doki N, Hata T, et al. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022 Jan 25;6(2):624-636.